Global Information
회사소개 | 문의 | 비교리스트

이식편대숙주병(GVHD) : 파이프라인 리뷰

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 11월 상품 코드 234335
페이지 정보 영문 671 Pages
가격
US $ 2,000 ₩ 2,478,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,957,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,436,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


이식편대숙주병(GVHD) : 파이프라인 리뷰 Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2019
발행일 : 2019년 11월 페이지 정보 : 영문 671 Pages

이식편대숙주병(GVHD)은 줄기세포 또는 골수 이식에 의해 이식된 도너의 새로운 세포가 이식 환자의 몸을 공격해 일어나는 합병증입니다. 증후는 복통 또는 극심한 복통, 구역, 구토, 설사, 건조하고 따끔한 통증의 눈, 황달, 호흡곤란, 질 건조 및 체중 감소 등입니다. 치료에는 면역 억제제를 사용합니다.

이식편대숙주병(GVHD) 치료법 관련 시장에 대해 분석했으며, 치료제 개발 및 임상시험의 최신 동향, 관련 기업 및 조직 개요, 개발중인 제품, 업계 최신 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

이식편대숙주병(GVHD) 개요

치료제 개발

이식편대숙주병(GVHD) : 치료제 평가

이식편대숙주병(GVHD)의 치료제 개발에 참여하고 있는 기업

약제 프로파일

이식편대숙주병(GVHD) : 휴지중인 프로젝트

이식편대숙주병(GVHD) : 개발이 중지된 제품

이식편대숙주병(GVHD) : 제품 개발 마일스톤

부록

도표

KSM 17.10.31

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 8: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 9: Products under Development by Companies, H2 2019
  • Table 10: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 11: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 12: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 13: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Table 14: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Table 15: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Table 16: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Table 17: Products under Development by Universities/Institutes, H2 2019
  • Table 18: Number of Products by Stage and Target, H2 2019
  • Table 19: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 20: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Table 21: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 22: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Table 25: Number of Products by Stage and Route of Administration, H2 2019
  • Table 26: Number of Products by Stage and Molecule Type, H2 2019
  • Table 27: Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2019
  • Table 28: Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H2 2019
  • Table 29: Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2019
  • Table 30: Graft Versus Host Disease (GVHD) - Pipeline by Alpine Immune Sciences Inc, H2 2019
  • Table 31: Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H2 2019
  • Table 32: Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H2 2019
  • Table 33: Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H2 2019
  • Table 34: Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, H2 2019
  • Table 35: Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, H2 2019
  • Table 36: Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H2 2019
  • Table 37: Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019
  • Table 38: Graft Versus Host Disease (GVHD) - Pipeline by Biocon Ltd, H2 2019
  • Table 39: Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2019
  • Table 40: Graft Versus Host Disease (GVHD) - Pipeline by BioIncept LLC, H2 2019
  • Table 41: Graft Versus Host Disease (GVHD) - Pipeline by BlueRock Therapeutics, H2 2019
  • Table 42: Graft Versus Host Disease (GVHD) - Pipeline by Boryung ViGenCell Inc, H2 2019
  • Table 43: Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Table 44: Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, H2 2019
  • Table 45: Graft Versus Host Disease (GVHD) - Pipeline by Celgene Corp, H2 2019
  • Table 46: Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd, H2 2019
  • Table 47: Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc, H2 2019
  • Table 48: Graft Versus Host Disease (GVHD) - Pipeline by Cellix Bio Pvt Ltd, H2 2019
  • Table 49: Graft Versus Host Disease (GVHD) - Pipeline by CheckPoint Immunology Inc, H2 2019
  • Table 50: Graft Versus Host Disease (GVHD) - Pipeline by Clinigen Group Plc, H2 2019
  • Table 51: Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd, H2 2019
  • Table 52: Graft Versus Host Disease (GVHD) - Pipeline by CTI BioPharma Corp, H2 2019
  • Table 53: Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc, H2 2019
  • Table 54: Graft Versus Host Disease (GVHD) - Pipeline by Cytopeutics Pte Ltd, H2 2019
  • Table 55: Graft Versus Host Disease (GVHD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
  • Table 56: Graft Versus Host Disease (GVHD) - Pipeline by Dualogics Corp, H2 2019
  • Table 57: Graft Versus Host Disease (GVHD) - Pipeline by Eli Lilly and Co, H2 2019
  • Table 58: Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SA, H2 2019
  • Table 59: Graft Versus Host Disease (GVHD) - Pipeline by enGene Inc, H2 2019
  • Table 60: Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2019, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 11, 38, 11, 2, 45, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Graft Versus Host Disease (GVHD) - Overview
  • Graft Versus Host Disease (GVHD) - Therapeutics Development
  • Graft Versus Host Disease (GVHD) - Therapeutics Assessment
  • Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
  • Graft Versus Host Disease (GVHD) - Drug Profiles
  • Graft Versus Host Disease (GVHD) - Dormant Projects
  • Graft Versus Host Disease (GVHD) - Discontinued Products
  • Graft Versus Host Disease (GVHD) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q